¹⁸F-fluorodeoxyglucose-PET as a biomarker in Huntington’s disease

Author： Ciarmiello Andrea Squitieri Ferdinando

ISSN： 1758-2024

Source： Neurodegenerative Disease Management, Vol.3, Iss.6, 2013-12, pp. : 489-491

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Clinical utility of flumazenil-PET versus [ 18 F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients

By Ryvlin P Bouvard S Le Bars De De Lamérie G Grégoire MC Kahane P Froment JC Mauguiére F

Brain, Vol. 121, Iss. 11, 1998-11 ,pp. : 2067-2081

Oxford University Press

Access to resources Recommend Favorite

Abnormal brain metabolism as a biomarker for evaluating therapeutic approaches in Huntington’s disease

By Parievsky Anna Cepeda Carlos Levine Michael S

Future Neurology, Vol. 7, Iss. 5, 2012-09 ,pp. : 527-530

Future Medicine

Access to resources Recommend Favorite

Spotlight on Huntington’s Disease

By Strupp Michael

Journal of Neurology, Vol. 251, Iss. 1, 2004-01 ,pp. : 120-121

Springer Publishing Company

Access to resources Recommend Favorite

HUNTINGTON’S DISEASE

By Barker Roger

Brain, Vol. 127, Iss. 1, 2004-01 ,pp. : 233-234

Oxford University Press

Access to resources Recommend Favorite

Early detection of Huntington’’s disease

By Paulsen Jane S

Future Neurology, Vol. 5, Iss. 1, 2010-01 ,pp. : 85-104

Future Medicine

Access to resources Recommend Favorite